期刊
NUTRIENTS
卷 15, 期 14, 页码 -出版社
MDPI
DOI: 10.3390/nu15143161
关键词
diet; hyperphosphatemia; peritoneal dialysis; phosphate; phosphate binders
Hyperphosphatemia is a common complication in advanced chronic kidney disease and can lead to cardiovascular morbidity and mortality. This review focuses on the management of phosphatemia in uremic patients receiving peritoneal dialysis. The control of serum phosphate in peritoneal dialysis patients is influenced by various factors such as patient transporter characteristics, peritoneal dialysis modalities, prescriptions, and diet. There is a need for more clinical trials specifically designed for peritoneal dialysis patients to evaluate the effects of multiple therapeutic approaches on serum phosphate control and clinical outcomes.
Hyperphosphatemia is a common complication in advanced chronic kidney disease and contributes to cardiovascular morbidity and mortality. The present narrative review focuses on the management of phosphatemia in uremic patients receiving peritoneal dialysis. These patients frequently develop hyperphosphatemia since phosphate anion behaves as a middle-size molecule despite its low molecular weight. Accordingly, patient transporter characteristics and peritoneal dialysis modalities and prescriptions remarkably influence serum phosphate control. Given that phosphate peritoneal removal is often insufficient, especially in lower transporters, patients are often prescribed phosphate binders whose use in peritoneal dialysis is primarily based on clinical trials conducted in hemodialysis because very few studies have been performed solely in peritoneal dialysis populations. A crucial role in phosphate control among peritoneal dialysis patients is played by diet, which must help in reducing phosphorous intake while preventing malnutrition. Moreover, residual renal function, which is preserved in most peritoneal dialysis patients, significantly contributes to maintaining phosphate balance. The inadequate serum phosphate control observed in many patients on peritoneal dialysis highlights the need for large and well-designed clinical trials including exclusively peritoneal dialysis patients to evaluate the effects of a multiple therapeutic approach on serum phosphate control and on hard clinical outcomes in this high-risk population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据